In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
5
0
0
0
Last 30D
1
0
0
0
0
1M Ago
1
0
0
0
0
2M Ago
2
2
0
0
0
3M Ago
1
3
0
0
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.6, a high estimate of $72.00, and a low estimate of $35.00. This current average represents a 1.29% decrease from the previous average price target of $53.29.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Ed Arce
HC Wainwright & Co.
Maintains
Buy
$58.00
-
Dae Gon Ha
Stifel
Announces
Buy
$48.00
-
Ed Arce
HC Wainwright & Co.
Maintains
Buy
$58.00
$58.00
Mani Foroohar
Leerink Partners
Lowers
Outperform
$43.00
$44.00
Jonathan Wolleben
JMP Securities
Raises
Outperform
$72.00
$69.00
Ed Arce
HC Wainwright & Co.
Raises
Buy
$58.00
$45.00
Josh Schimmer
Cantor Fitzgerald
Raises
Overweight
$40.00
$35.00
Ed Arce
HC Wainwright & Co.
Lowers
Buy
$45.00
$58.00
Jonathan Wolleben
JMP Securities
Raises
Market Outperform
$69.00
$64.00
Josh Schimmer
Cantor Fitzgerald
Maintains
Overweight
$35.00
-
Key Insights:
Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...Full story available on Benzinga.com
Benzinga
